The main predictive biomarkers for the response to anti-EGFR monoclonal antibodies-targeted therapy in metastatic CRC are mutations in the KRAS, NRAS, and BRAF genes [8,9] that explain the low percentage of CRC patients (10–20%) responsive to anti-EGFR monoclonal antibodies single treatment [4]. Here, BRAF is linked to colorectal carcinoma.